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Effect of ribonucleic acid perfusion 
on canine kidney and 
liver homograft survival 
M any of tho problIn~ of o'gall tran,-
plantation could be minimized if it were pos-
sible to mitigate graft rejection by modifying 
the transplanted tissue rather than the host 
immunologic response. Efforts to achieve this 
objective have been unsuccessful, with occa-
sional possible exceptions,4, 9, 11 of which the 
most intriguing was described by Jolley, Hin-
shaw, and PetersonY They reported that 
rabbit skin grafts which were first immersed 
in homologous ribonucleic acid (RNA) and 
then transplanted to recipient animals which 
were given intravenous RNA had a survival 
4 times longer than controls. The role of the 
preliminary soaking was not analyzable in 
these experiments, but the authors also re-
ported that human skin homografts subjected 
only to RNA soaking had unusually pro-
tracted viability when placed upon patients 
with burns.'o Similar attempts to "pretreat" 
whole organ homografts have so far been 
unsuccessful. 21 
In our experiments, this concept has been 
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examined in dogs by perfusing kidney and 
liver homografts with RNA prepared from 
the spleens of the prospective recipients 
(autologous RNA) or other dogs (homolo-
gous RNA). After transplantation to un-
modified recipients, about one fourth of these 
life-sustaining organs had a definitely pro-
longed functional survival. 
METHODS 
Mongrel dogs weighing 10.5 to 25.9 kilo-
grams were used. Anesthesia was with sodium 
pentobarbital supplemented with the tran-
quilizer phencyclidine hydrochloride (Ser-
nylan). Litter mates were never used, and 
donor-recipient combinations were selected 
on the basis of dissimilar appearance of the 
animals. Renal homotransplantation was to 
the standard pelvic site and the animals' own 
kidneys were removed at the same operation. 
Orthotopic liver transplantation was per-
formed after total recipient hepatectomy. 
After both kinds of transplantation, anti-
biotics were given. No immunosuppressive 
agents were used. Recipients which died in 
less than 5 days because of homograft vas-
cular thrombosis, intussusception, or pneu-
monitis were excluded; further mention will 
be made only of the retained experiments. 
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This did not bias the results, since the loss 
rate was 10 of 40 (25 percent) in the com-
bined control groups as compared to 16 of 
56 (28 percent) in the test series. 
The criteria used to evaluate the results 
included survival times, the quality of organ 
function just prior to death, and histologic 
studies of the retrieved homografts. For the 
last purpose, all tissues were fixed at the 
time of autopsy in 10 percent formalin. For 
survival computation, maximum credit for 
individual dogs was limited to 70 days. 
RNA was prepared from nonwashed, 
quick-frozen dog spleens by phenol extrac-
tion. The method of Scherrer and Darnelp2 
was used, except that bentonite added to a 
final concentration of 0.04 percent was used 
instead of polyvinyl sulfate as a ribonuclease 
inhibitor and re-extraction was done only 
once. The final precipitate had the ultra-
violet absorption spectrum characteristic for 
RNA with a maximum at 260 mIL and a 
280: 260 mIL ratio of 1: 1. 72 to 1: 2.34 (mean, 
1.98). The DNA content was less than 2.0 
percent measured with the diphenylamine 
method and the protein content was lower 
than 0.1 percent as determined by the phenol 
biuret reaction. Before use, the frozen RNA 
precipitate was dissolved to a concentration 
of 0.5 to 1.6 mg. per milliliter in cold lac-
tated Ringer's solution (5° C.) which con-
tained 5 mg. per 100 ml. procaine and 
enough phosphate buffer to adjust the pH 
to 7.45 to 7.55. In various test groups other 
constituents were added as outlined below. 
The general technique of perfusion was 
the same in all the test and control groups. 
The excised organs were first cleared of blood 
by intravascular infusion of cold (5° C.) 
lactated Ringer's solution. This was followed 
by 50 and 100 ml. of the chilled special solu-
tions for the kidneys and livers, respectively. 
At the completion of perfusion, the kidneys 
were placed in a refrigerator at 5° C. for 15 
minutes and then transplanted to their new 
host. Transplantation of the livers was started 
immediately. Thus, exposure to the portion 
of the test solutions which remained in the 
organs was variable, ranging from 35 to 65 
minutes. Ischemia times for the kidneys 
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ranged from 43 to 75 minutes and for the 
livers from 51 to 64 minutes. 
MATERIAL 
The experimental and control series all 
involved renal transplantation except for 
Group 2B. They were divided as follows: 
Group 1. Autologous RNA (10 dogs). The 
spleens of the eventual recipients were re-
moved 2 to 5 days before transplantation and 
used as the RNA source (Fig. 1) for renal 
homograft perfusion. 
Group 2. Autologous RNA plus DEAE-
dextran (17 dogs). The perfusate was the 
same as in Group 1 except that high molecu-
lar weight DEAE-dextran* was added. This 
change was made because of the reports that 
DEAE-dextran enhances the infectivity of 
viral RNA!O (A) Renal homografts (10 
dogs), 1.0 mg. per milliliter DEAE-dextran 
was added; and (B) liver homografts (7 
dogs), 0.3 mg. per milliliter DEAE-dextran 
was added. 
Group 3. Homologous RNA (10 dogs). 
The RNA was prepared from the spleen of a 
different dog than the homograft recipient 
or donor (Fig. 1). Otherwise the renal ho-
mograft perfusion was as in Group 1. Re-
cipient splenectomy was performed at the 
time of transplantation. 
Group 4. Homologous RNA plus DEAE-
dextran (10 dogs). The experiments were 
as in Group 3 except that 1.0 mg. per milli-
liter DEAE-dextran was added to the per-
fusate. 
Group 5. Control. Homologous RNA plus 
ribonuclease (10 dogs). One hour before the 
experiment, 5 ILg commercial ribonucleaset 
(RNase) per 1.0 mg. RNA was added to the 
perfusate at room temperature. Otherwise, 
the procedure was as in Group 3. 
Group 6. Control. DEAE-dextran (10 
dogs). The same dextran-containing per-
fusate was used as in Groups 2 and 4, ex-
cept that RNA was omitted. 
Group 7. Control. No additive (10 dogs). 
*Diethylaminoethyl-dextran prepared from dextran, Mw 
=2 X 1()6, Pharmacia, Piscataway, N. J. 
tBeef pancreas ribonuclease, Worthington Biochemical 
Corporation, Freehold, N. J. 
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Kidney reclpients 
Fig. 1. Treatment of renal homo grafts with RNA. 
Homograft perfusion was with unmodified 
lactated Ringer's solution; ischemia times and 
other procedural details were as in Groups 
1 to 6. 
Group 8. Homologous RNA and renal 
autotransplantation (12 dogs). The kidneys 
were removed, perfused with homologous 
RNA solution as in Group 3, and trans-
planted to the standard pelvic site. Splenec-
tomy was performed at the same operation. 
RESULTS 
Survival and function. The results with 
renal homotransplantation are summarized 
in Table I. When the homografts were per-
fused with the 3 control solutions (Groups 
5 to 7), one recipient animal in each series 
of 10 lived for more than 20 days, the maxi-
mum being 44 days. Mean survival in the 
3 groups ranged from 12.6 to 13.4 days. 
Uremia developed in every instance. 
In contrast, there were several examples 
of prolonged survival in each series in which 
the homografts were treated with RNA 
(Groups 1 to 4), and the mean survival was 
increased to 17.6 to 24.2 days. The results 
were comparable with autologous and ho-
mologous RNA and were not significantly 
influenced by the addition of DEAE-dextran 
to the perfusate. Of the 40 recipients in the 
combined test groups, 17, 11, 8, and 5 lived 
for more than 15, 20, 30, and 40 days, re-
spectively. The longest survival was 123 
days; in this animal the BUN was less than 
35 mg. percent during the first 90 postop-
erative days (Fig. 2). In 5 other animals 
which died of pneumonitis and wasting af-
ter 11, 16, 21, 33, and 55 days, BUN's 
determined from 1 to 3 days before death 
were normal. The remaining 35 animals de-
veloped uremia. When compared to all the 
control series, the prolongation in survival 
(Table I) in the combined test groups was 
statistically significant (p < 0.025). 
Nine of the 12 dogs in which renal auto-
grafts were first perfused with homologous 
RNA (Group 8) lived until being killed 8 to 
79 days postoperatively. At the time of killing 
all 9 animals had a normal BUN. The other 
3 dogs died within 7 to 11 days, 2 with 
uremia and one for inapparent reason. 
In all the foregoing series in which DEAE-
dextran was used in a concentration of 1.0 
mg. per milliliter, it was noted that the kid-
neys were initially revascularized unevenly. 
There were multiple islands of cyanosis which 
often required an hour or more to disappear 
after restoration of the blood supply. Within 
surface vessels gross aggregates of red cells 
were visible. These were never seen when 
only RNA or lactated Ringer's solution was 
used. 
A similar red cell aggregation was noted 
when 1.0 mg. per milliliter DEAE-dextran 
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Fig. 2. The course in a dog that lived 123 days after receipt of a renal homograft perfused 
with homologous RNA plus DEAE-dextran. The final uremia was due to obstruction of the 
ureteroneocystostomy by a calculus. The homograft showed no histologic evidence of rejection. 
Table I. Survival in recipients of renal homografts 
Survival No. of dogs surviving No. of No. dogs with 
of ( days) 15 
I 
20 
I 
30 
I 
40 nonrejected 
Group dogs Mean* I S.D. I Range days days days days homografts 
Test group 
1. Autologous RNA 10 17.8 13.8 9- 55 5 2 
2A. Autologous RNA plus 
DEAE-dextran 10 18.6 11.5 11- 47 4 3 1 1 
3. Homologous RNA 10 17.6 12.5 5- 40 4 3 3 2 
4. Homologous RNA plus 
DEAE-dextran 10 24.2 21.1 9-123 4 3 3 2 3 
-
Total 17 11 8 5 7 
Control groups 
5. Homologous RNA plus 
RNase 10 12.6 4.0 8- 22 2 0 0 0 
6. DEAE-dextran 10 13.1 11.3 6- 44 2 1 1 0 
7. Lactated Ringer's solu-
tion 10 13.4 7.8 7- 35 1 1 0 0 
- -
Total 5 3 2 0 
*FQr computation of means the maximum credit for individual dogs was limited to 70 days. 
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was used in the perfusate for hepatic homo-
grafts. Two such livers developed fatal acute 
outflow block. Consequently, the dose of 
DEAE-dextran per milliliter of RNA per-
fusate was reduced to 0.3 mg. per milliliter. 
Seven livers perfused with this modification 
and transplanted as orthotopic homografts 
supported life for 46, 14, 13, 11, 7, 7, and 
7 days. The average was 15.0 ± 14.0 (S.D.) 
days. Specific control experiments were not 
performed but in a recent series of 15 un-
treated dogs in our laboratory the mean sur-
vival was 8.0 ± 1. 7 (S.D.) days with a range 
of 6 to 11 days. To our knowledge, the 
longest survival ever obtained after orthotopic 
liver transplantation to an unmodified canine 
recipient was 31 days.12 
Pathologic studies. The 30 renal homo-
grafts in the 3 groups of control animals were 
all rejected (Table I). The evidence for re-
jection was dense infiltration of the inter-
stitium by mononuclear cells, focal fibrinoid 
necrosis of the walls of the arterioles and 
interlobular arteries, foci of cortical necrosis, 
and scattered interstitial hemorrhages. An 
average of 38 percent of the infiltrating cells 
had pyroninophilic cytoplasm. In one animal 
that lived for 44 days (Group 6), there were 
in addition P.A.S.-positive deposits on the 
glomerular capillary basement membranes. 
All the homografts were swollen because of 
interstitial edema. 
Seven of the 40 renal homografts that had 
been perfused with RNA showed no evi-
dence of rejection (Table I). The other 33 
kidneys were rejected and did not differ from 
the controls. Two of the 7 animals not dying 
of rejection died from uremia 11 and 123 
days after transplantation. In the first case 
the kidney was in the healing phase following 
acute tubular necrosis presumably inflicted at 
the time of transplantation. In the other dog 
calculi formed in the homograft, obstructed 
the ureter at the ureteroneocystostomy, and 
led to hydronephrosis and uremia. The re-
maining 5 homografts which had been re-
trieved 11 to 55 days after transplantation 
from dogs dying of pneumonia and wasting 
were normal. 
There was nothing suggestive of rejection 
in the 12 renal autografts treated with ho-
mologous RNA (Group 8). Autografts from 
the 2 dogs that died of uremia 7 and 11 days 
posttransplantation were infarcted though 
the renal artery and vein had appeared 
patent at autopsy. 
Of the 7 liver homografts perfused with 
autologous RNA plus DEAE-dextran, all 
showed evidence of rejection with dense 
mononuclear cell infiltration around the por-
tal and central veins and necrosis of the 
centrilobular and midzonal hepatocytes. 
DISCUSSION 
RNA has been used in 2 ways in attempts 
to modify homograft rejection. It has been 
administered to recipient animals, as first 
reported by Ashley and associates2 who 
claimed a resultant prolongation of skin 
graft survival. Their observations have been 
confirmed by two groups of investigatorsll, 13 
and denied by a thirdY In Ashley's study 
and those of Lowe and Axelrod,13 there was 
potentiation of homograft survival only if 
donor-specific RNA was used, although Jol-
ley, Hinshaw, and Petersonll claimed the 
same effect for nonspecific homologous RNA. 
Alternatively, RNA has been used by Jol-
ley and Hinshaw10 to locally treat skin homo-
grafts prior to their transplantation. In their 
experiments, skin was obtained from human 
cadaver donors, soaked in heterologous (calf 
liver) soluble RNA, and transferred to the 
granulating wounds of burned patients. The 
homografts apparently survived for 5 weeks 
to 21 months. 
The results in the present canine study are 
in general accord with those reported by 
Jolley and Hinshaw. A shorter period of per-
fusion with an RNA extract resulted in the 
prolongation of function of a moderate num-
ber of transplanted kidneys and livers. The 
effect was not increased by the addition to 
the perfusate of DEAE-dextran, a presumed 
RN ase inhibitor,20 but it was abolished by 
the addition of commercial RNase. 
In such experiments the reason is not 
known for the apparent privilege endowed 
upon homografts by preliminary treatment 
with RNA. There is abundant evidence that 
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fundamental alterations can be induced in 
mammalian cells briefly exposed to exogenous 
RNA and that some of them can persist for 
some time. Such changes, which have been 
ascribed to the introduction of new genetic 
information by the messenger fraction of the 
RNA, can be broadly grouped in those 
of function1 , 6, 16-19, 24 or structure.7 , 19, 23 It 
might be reasoned that the messenger RNA 
known to be present in the extract used in 
our experiments14 could have directed a 
change in the antigenicity of the homograft 
cells. 
Against this explanation was the fact that 
rejection was delayed as effectively by organ 
treatment with homologous as with recipient-
specific (autologous) RNA. Furthermore, if 
the increased graft survival were due to in-
duced change in the genetic characteristics 
of the homograft cells, it would be expected 
that autografts treated with homologous 
RNA would undergo at least temporary re-
jection. This has been said to occur in skin 
grafts in two reports,5, 8 a finding which 
could not be confirmed by Askonas and 
associates3 or in the present study. Jolley 
and Hinshaw10 similarly concluded that the 
protective effect of RNA on homografts was 
by another mechanism, possibly involving a 
change in cell membrane permeability. 
Further work will be necessary to deter-
mine if these results have practical implica-
tion in clinical transplantation. The increase 
in homograft survival was limited, but 7 of 
the 40 renal homografts never developed 
evidence of rejection. When rejection oc-
curred, however, it was quite severe and in-
distinguishable from that in the untreated 
animal. Thus, if RNA conditioning of homo-
grafts proves to be useful, the benefit can be 
expected to be a limited one. It will be in-
teresting to determine whether or not graft 
conditioning can be advantageously com-
bined with effective host immunosuppression. 
SUMMARY 
Canine renal and hepatic homografts were 
perfused prior to transplantation with RNA 
prepared from the spleens of the prospective 
recipients or other indifferent dogs. After 
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conditioning with either recipient-specific 
(autologous) or indifferent (homologous) 
RNA, about a fourth of the homografts sub-
sequently had prolonged function. Maximum 
survival for the recipients of the kidneys and 
livers was 123 and 46 days, respectively. The 
effect was not increased by the addition of 
a supposed RNase inhibitor, DEAE-dextran, 
but it was abolished by the addition of com-
mercial RNase. The treatment of renal auto-
grafts with homologous RNA did not result 
in their rejection. The latter finding and the 
fact that the results after homotransplanta-
tion were equivalent with either homologous 
or autologous RNA suggest that the homo-
graft protection was not due to RNA-in-
duced changes in the genetic characteristics 
of the cells. 
We wish to thank Mrs. M. Berenbein, B.S., for 
excellent technical assistance. 
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DISCUSSION 
Dr. Joseph E. Murray (Boston, Mass.). The 
principle of altering the donor rather than the 
recipient is instinctively appealing because the 
possibility of ex vivo pretransplant therapy to the 
donor organ adds no morbidity to the recipient 
and may diminish the need for genetic matching 
of donor and recipient. 
The possible mechanisms of altering the donor 
organ are to change the genetic structure, as 
mentioned by Dr. Groth, to block release of the 
antigen, or to cover the antibody receptor sites. 
The experiments of Dr. Groth and his co-workers 
used such a short duration and low-flow perfusion 
that it is promising that any beneficial effect was 
produced. The nonspecificity of the result is not 
surprising. 
The mechanism of action in these experiments 
might be delayed recognition of the antigen by 
the host lymphocytes as they circulate through 
the graft because, as Strober and Gowans showed 
clearly, antigen is recognized and processed via 
lymphocytes traversing the kidney. Possibly the 
pretransplant RNA therapy covered antigen recog-
nition areas in such a way as to make them less 
vulnerable to the lymphocyte. 
One previous experiment of ours may be perti-
nent. When long-functioning renal allografts in 
dogs are retransplanted into their original hosts, 
they are not rejected. Certainly, long residence in 
allogeneic hosts, in many instances beyond a year, 
affords ample opportunity for some genetic change 
to occur in the graft. Nevertheless, in these ex-
periments no antigenicity was added by such pro-
longed perfusion. 
Finally, the concept of "adaptation" by means 
of blocking antibodies are promising problems in 
current clinical organ transplantation. As we well 
know, most kidney transplants which are destined 
to fail do so within the first 3 months following 
transplantation. It is during these 3 months that 
the host-donor readjustment occurs, "adaptation," 
if we wish to use the term. This is most likely 
mediated by the formation of protective or block-
ing antibodies. Perhaps the late survival is by a 
secondary mechanism, a final common pathway, 
quite unrelated to the particular immunosuppres-
sive regimens used at the beginning. 
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These two papers of Dr. Groth and Dr. Rapa-
port suggest two ways to minimize the hard core 
of early transplant failures; with a slight boost, 
either by antigen pretreatment of the host or by 
ex vivo RNA perfusion of the donor, the grafted 
organ might be shepherded through that difficult 
honeymoon of the first 3 months and lead to a 
compatible permanent marriage. 
Dr. Ronald A. Malt (Boston, Mass.). The con-
trol groups that Dr. Groth and his colleagues used 
and the tests of statistical significance leave no 
doubt about the fact that perfusion with RNA 
increases the length of time the transplanted kid-
ney functions and delays or prevents rejection. 
I should therefore like to confine my remarks 
to asking the group whether they have had time 
to work on the mechanism for this particular phe-
nomenon, so that the active principle can be 
exploited. 
First of all, is it possible that it is a nonspecific 
effect of the RNA macromolecules being adsorbed 
on the surface of the kidney cells? This could 
easily be proved by trying to wash the kidneys 
afterward or by the use of other macromolecular 
substances. 
Second, is it possible that the RNA extracted 
by this technique-which is principally ribosomal 
RNA and somewhat degraded-entered into the 
cells, and although it did not change the infor-
mation capacity of the cells, decoyed the protein 
synthesizing mechanism into trying to synthesize 
false proteins on nonsense RNA templated? 
Finally, I should like to question the role of 
ribonuclease. We know that ribonuclease will pene-
trate from the outside of kidney cells to the in-
side. In one of the control groups in which ribo-
nuclease was employed, the standard deviation was 
much smaller than in any other group, indicating 
that there may have been some consistent effect of 
ribonuclease in causing kidney rejection. Further-
more, we know from attempts to prepare kidney 
RNA that lactated Ringer's solution activates ribo-
nuclease in the kidney, and the only way we can, 
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in fact, prepare electrophoretically undergraded 
RNA from kidneys is by adding a large amount 
of RNA to the mixture. So I ask, finally, whether 
the RNA could have been acting as a sponge to 
sop up a lot of ribonuclease otherwise activated 
by perfusion and ischemia in the donor kidney. 
Dr. John A. Mannick (Boston, Mass.). Several 
years ago we attempted to accomplish the same 
end by a slightly different system; namely, at-
tempting to suppress the reactivity of sensitized 
lymphocytes by exposure to RNA from the ani-
mal whose tissues were used to sensitize the cells. 
We came to conclusions similar to those of Dr. 
Groth; namely, that this suppressive effect of RNA 
was nonspecific. In other words, we had no evi-
dence that we had altered the genetic or epi-
genetic character of these cells by exposure to 
RNA. 
We felt that perhaps the best explanation was 
some kind of cell-coating phenomenon. 
We found one interesting sidelight observation, 
and that was that liver RNA, as opposed to 
lymphoid RNA, was totally ineffective, and I 
wonder if Dr. Groth has tried RNA extracted 
from other than a lymphoid organ in his experi-
ments. 
Dr. Groth (closing). The interesting sugges-
tions concerning the underlying mechanism by 
Dr. Murray and the very intriguing suggestions 
that were made by Dr. Malt are fascinating to me. 
However, we have so far no data that can explain 
why RNA prolongs homograft survival, and I 
think we have to conclude for the moment that 
the mode of action of the RNA in this kind of 
experiment is unknown. We would certainly like 
to explore this further. 
We have not used anything but RNA extracted 
from spleens. We intend to try unspecific heterolo-
gous RNA, RNA that you can buy from any 
chemical company. If that would work, this would 
certainly make things easier. The phenol extrac-
tion takes some time. 
